A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
Clinical trial NCT05221840 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05221840
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-02-07
- Primary completion
- 2026-09-30
- Enrollment
- 1051
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.